Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0270 + Everolimus vs Physician's Choice in ER+/HER2- Advanced Breast Cancer
NCT06680921Phase 3Active, not recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Aug 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SIM0270 in breast cancer (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2024; status: active, not recruiting.
02
Drugs
SIM0270
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06680921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680921.